CRDF Latest Press Releases

-- October 27, 2026 --

Cardiff Oncology Appoints Leila Alland, MD, as Interim Chief Medical Officer Globe Newswire 4:05 PM

-- October 21, 2026 --

Cardiff Oncology Receives FDA Orphan Drug Designation for Onvansertib in Chronic Myelomonocytic Leukemia Globe Newswire 4:05 PM

-- September 14, 2026 --

Cardiff Oncology and Nerviano Medical Sciences Amend their 2017 Exclusive License Agreement Globe Newswire 8:30 AM

-- September 2, 2026 --

Cardiff Oncology to Participate in September 2026 Conferences Globe Newswire 7:00 AM

-- August 11, 2026 --

Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update Globe Newswire 4:10 PM

-- July 15, 2026 --

Cardiff Oncology Announces $10 Million Registered Direct Offering Globe Newswire 8:00 AM

-- June 2, 2026 --

Cardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual Meeting Globe Newswire 9:06 AM

-- June 1, 2026 --

Cardiff Oncology to Participate in the Jefferies Global Healthcare Conference Globe Newswire 4:01 PM

Market Data Delayed 15 Minutes